The Experiences of Patients Living With Malignant Pleural Effusions

NCT ID: NCT03235999

Last Updated: 2025-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-02

Study Completion Date

2019-01-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Up to 20 patients with malignant pleural effusions will be interviewed about their experiences of having this condition and its management.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Pleural Effusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Talc pleurodesis

Up to 10 patients who have had talc pleurodesis

No interventions assigned to this group

IPC

Up to 10 patients who have had indwelling pleural catheters (IPC)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults diagnosed with a malignant pleural effusion
2. Has undergone either talc pleurodesis or IPC
3. Have signed a consent form prior to entering the study
4. Life expectancy \> 6 weeks based on LENT guidelines (Low/Moderate risk group) - The LENT score calculation assigns 0 (\<1500 IU/L) or 1 (\>1500 IU/L) for pleural fluid LDH level; 0 to 3 points for matching ECOG performance scores (3 and 4 are combined); 0 (\<9) or 1 (\>9) for neutrophil-to-lymphocyte ratio; and 0 (lowest risk), 1 (moderate risk), or 3 (highest risk) for tumor type.

Exclusion Criteria

1. Any patient who is unable to understand sufficient English to take part in the semi-structured interviews
2. Weakness or fatigue sufficient so that the patient is unable to take part in the interviews
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gloucestershire Hospitals NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Perkins, MBBCh

Role: PRINCIPAL_INVESTIGATOR

Gloucestershire Hospitals NHS Foundation Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gloucestershire Hospitals NHS Foundation Trust

Cheltenham, Gloucestershire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16/009/GHT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pleurodesis in Small-bore Chest Tube
NCT07208409 NOT_YET_RECRUITING NA